Cipla Limited on Monday announced the launch of an orally inhaled insulin powder for diabetes management in India, offering patients a convenient, needle-free alternative to traditional injectable insulin therapy.
The Mumbai-based drug maker said it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) late last year for the exclusive distribution and marketing of Afrezza, a rapid-acting inhalable insulin.
Cipla said the introduction of the product is expected to benefit a large section of India’s diabetes population, with nearly 10 crore adults currently living with diabetes mellitus, by improving ease of use and treatment adherence.